Fundraising Fox
Arnatar Therapeutics
7 known investors
Find your way into Arnatar Therapeutics
Sign up to find every way you can get introduced to Arnatar Therapeutics
- Your email: who you already know at Arnatar Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Arnatar Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Arnatar develops a next-generation RNA discovery platform called DARGER that combines gene silencing and gene upregulation technologies for oligonucleotide therapeutics. The platform serves pharmaceutical researchers and biotechnology companies developing treatments for genetic disorders and other disease areas.
Founders & leadership
Investors · 7
How we know: the company's own site · the VCSheet dataset · Not right? Tell us
How we know: F-Prime Capital's portfolio page · Not right? Tell us
How we know: funding news · the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcementsSource: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Arnatar Therapeutics do?
- Arnatar develops a next-generation RNA discovery platform called DARGER that combines gene silencing and gene upregulation technologies for oligonucleotide therapeutics. The platform serves pharmaceutical researchers and biotechnology companies developing treatments for genetic disorders and other disease areas.
- Who founded Arnatar Therapeutics?
- Arnatar Therapeutics was founded by Dr. Xuehai Liang, Dr. Yanfeng Wang.
- Who are Arnatar Therapeutics's investors?
- Arnatar Therapeutics's investors include 3E Bioventures Capital, F-Prime Capital, Apricot Capital, Eight Roads Ventures, Gaorong Ventures, Legend Star, New Alliance Capital.